Tyson Eliot Marshall Sells 22,889 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall sold 22,889 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $21.47, for a total transaction of $491,426.83. Following the transaction, the general counsel directly owned 345,442 shares in the company, valued at approximately $7,416,639.74. This trade represents a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Tyson Eliot Marshall also recently made the following trade(s):

• On Thursday, November 20th, Tyson Eliot Marshall sold 70,000 shares of Alphatec stock. The shares were sold at an average price of $19.51, for a total transaction of $1,365,700.00.

Alphatec Trading Up 1.1%

Shares of ATEC opened at $20.90 on Thursday. Alphatec Holdings, Inc. has a twelve month low of $8.69 and a twelve month high of $22.66. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 43.02. The firm has a market capitalization of $3.10 billion, a P/E ratio of -20.10 and a beta of 1.08. The firm’s 50-day moving average is $18.18 and its two-hundred day moving average is $15.00.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to analysts’ expectations of $182.78 million. During the same period last year, the firm earned ($0.28) EPS. Alphatec’s revenue was up 30.4% compared to the same quarter last year. On average, research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alphatec

Institutional investors and hedge funds have recently modified their holdings of the company. Nuveen LLC purchased a new stake in Alphatec in the 1st quarter worth approximately $135,874,000. Vanguard Group Inc. boosted its holdings in shares of Alphatec by 2.4% during the third quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company’s stock worth $99,091,000 after purchasing an additional 158,295 shares during the last quarter. American Century Companies Inc. grew its position in shares of Alphatec by 2.6% in the third quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company’s stock valued at $92,133,000 after purchasing an additional 159,330 shares during the period. Royal Bank of Canada increased its stake in Alphatec by 10.8% in the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock valued at $35,773,000 after purchasing an additional 342,656 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Alphatec by 7.4% during the second quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company’s stock worth $29,946,000 after buying an additional 185,297 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ATEC. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price target (up previously from $20.00) on shares of Alphatec in a research note on Friday, October 31st. Stifel Nicolaus assumed coverage on shares of Alphatec in a research report on Tuesday, October 28th. They set a “buy” rating and a $20.00 target price for the company. Morgan Stanley set a $23.00 price target on shares of Alphatec in a report on Tuesday, December 2nd. Needham & Company LLC raised their price objective on shares of Alphatec from $16.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, Loop Capital set a $25.00 target price on Alphatec in a research note on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.45.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.